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ABSTRACT
Objective To examine recent trends of acute infection
with hepatitis B virus (HBV) in Japan by nationwide
surveillance and phylogenetic analyses.
Methods During 1991 through 2009, a sentinel
surveillance was conducted in 28 national hospitals in
a prospective cohort study. Genotypes of HBV were
determined in 547 patients with acute hepatitis B.
Nucleotide sequences in the preS1/S2/S gene of
genotype A and B isolates were determined for
phylogenetic analyses.
Results HBV genotype A was detected in 137 (25%
(accompanied by genotype G in one)) patients, B in 48
(9%), C in 359 (66%), and other genotypes in the
remaining three (0.5%). HBV persisted in five with
genotype A including the one accompanied by genotype
G; another was co-infected with HIV type 1. The
genotype was A in 4.8% of patients during 1991e1996,
29.3% during 1997e2002, and 50.0% during
2003e2008 in the capital region, as against 6.5%, 8.5%
and 33.1%, respectively, in other regions. Of the 114
genotype A isolates, 13 (11.4%) were subgenotype A1,
and 101 (88.6%) were A2, whereas of the 43 genotype
B isolates, 10 (23.3%) were subgenotype B1, 28 (65.1%)
were B2, two (4.7%) were B3, and three (7.0%) were
B4. Sequences of 65 (64%) isolates of A2 were identical,
as were three (23%) of A1, and five (18%) of B2, but
none of the B1, B3 and B4 isolates shared a sequence.
Conclusions Acute infection with HBV of genotype A,
subgenotype A2 in particular, appear to be increasing,
mainly through sexual contact, and spreading from the
capital region to other regions in Japan nationwide.
Infection persisted in 4% of the patients with genotype
A, and HBV strains with an identical sequence prevailed
in subgenotype A2 infections. This study indicates the
need for universal vaccination of young people to prevent
increases in HBV infection in Japan.
Hepatitis B virus (HBV) has been classified into 10
genotypes, designated AeJ, based on a >8% diver-
gence in the full-genome sequence.1e7 Different
genotypes are associated with distinct clinical
manifestations, such as severity and progression of
liver disease, as well as response to antiviral
treatments.8e10 Some genotypes are subclassified:
genotype A into at least two subgenotypes, A1
(Asian/African type) and A2 (European type)11e13;
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Significance of this study
What is already known about this subject?
< In Japan, a national prevention programme was
started in 1986 with selective vaccination of
babies born to mothers who carry hepatitis B
virus (HBV). Since then, the prevalence of
hepatitis B surface antigen among younger
generations has decreased sharply.
< However, retrospective studies indicate that the
frequency of HBV genotype A is increasing
among patients with acute hepatitis B (AHB)
within the capital region of Japan.
< Infection with genotype A more often persists
than infection with other genotypes.
< Because there is no reliable and comprehensive
surveillance system for AHB in Japan, the
incidence of AHB and factors responsible for
changes over many years are not known.
What are the new findings?
< This is a prospective cohort study for surveil-
lance of AHB throughout Japan in a national
research programme.
< The incidence of AHB in Japan has not
decreased, because genotype A infections
have increased over time.
< Genotype A infections started to increase in the
capital region of Japan, and then spread to other
regions 5e6 years later.
< About 90% of genotype A found in AHB patients
in Japan is subgenotype A2.
< Subgenotype A2 isolates from patients with
AHB tend to preserve sequence identity over
time, indicating that particular subgenotype
A2 strains have been transmitted without
undergoing mutations.
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B into B1 (Japanese type) and B2 (Asian type)14 15; and C into
C1 (Southeast-Asian type) and C2 (East-Asian type).16 Subge-
notypes also influence the replication of HBV and clinical
manifestation.15 17 18
According to a report from Japan in 2001,19 genotype C was
the most prevalent (84.7%), followed by genotype B (12.2%) and
A (1.7%), among patients with chronic hepatitis B. In 2002,
genotype A became the most prevalent in patients with acute
hepatitis B (AHB) around Tokyo, the capital region of Japan.20 21
Several reports have shown that infection with HBV genotype A
is associated with particular sexual behaviours, such as homo-
sexual activity and promiscuous sexual contacts, and tends to
persist longer than that with HBV genotype C.22 23 These
reports have raised concerns about the horizontal HBV infection
in adults, which, in general, is considered to resolve spontane-
ously. However, adult-acquired HBV infection may result in
chronic HBV infection in some instances.
Information on changes in genotype distribution over time, as
well as genotype-specific clinical manifestations, may help in
planning preventive measures and antiviral therapy strategies.
Therefore it is important to examine how genotype A infection
has spread in Japan, and what clinical and virological charac-
teristics it possesses.
We have been conducting a nationwide, sentinel surveillance
on acute viral hepatitis for more than 30 years. As part of this
surveillance, a prospective cohort study has been conducted on
547 patients with AHB in 28 medical centres over the 19 years
from 1991 to 2009. Geographical and longitudinal distributions
of HBV genotypes/subgenotypes were surveyed, and their
influence on clinical outcome was evaluated.
PATIENTS AND METHODS
Patients
A total of 681 patients with sporadic AHB were enrolled
consecutively in a survey carried out by the Japan National
Hospital Acute Hepatitis Study Group (JNHAHSG). They were
admitted to 28 national hospitals from January 1991 to the end
of December 2009. They were grouped geographically into two
areas: the capital region (Gunma, Saitama, Tokyo and Kana-
gawa) and other regions (figure 1). Patients were also longitu-
dinally categorised into three periods: 1st (1991e1996), 2nd
(1997e2002) and 3rd (2003e2008). In addition, the year 2009
provided the most recent data. Of the 681 patients, 547 (80.3%)
entered the study, for whom serum samples were available on
admission and had been stored at 208C.
The diagnosis of AHB was based on the following criteria: (1)
acute onset of liver injury without a history of liver dysfunction;
(2) detection of hepatitis B surface antigen (HBsAg) in the
serum; (3) positivity for IgM antibody to HBV-core antigen
(IgM anti-HBc) in high titres (detectable in sera diluted 10-fold);
and (4) absence of past or family history of chronic HBV
infection. Severe acute hepatitis (SAH) was defined as
prothrombin time (PT) #40% and hepatic encephalopathy of
grade #I. Fulminant hepatitis (FH) was diagnosed from PT
#40% and hepatic encephalopathy of grade $II. Patients in
whom HBsAg remained in the serum for >6 months after onset
were considered to have acquired chronic HBV infection. The
following information was collected from each patient: year and
age at onset, gender, residential area, HBsAg, IgM anti-HBc,
alanine aminotransferase, total bilirubin, PT, severity of liver
disease, mortality, routes of transmission, sexual behaviours,
travelling abroad in recent past, HBV genotype, mutations in
precore (PreC) and core promoter (CP) regions, and RNA of
hepatitis D virus. Antibody to HIV type 1 (anti-HIV) was
Figure 1 Locations of participating hospitals in Japan. Hospitals in the
capital region (M1eM8) are indicated by eight closed circles, and those
in other regions (O9eO28) by 20 open circles. Numbers in parentheses
indicate the total number of enrolled subjects for each site. The hospitals
are: M1, Nishigunma Hospital, Gunma; M2, Nishisaitama-Chuo Hospital,
Saitama; M3, National Disaster Medical Center, Tokyo; M4, Tokyo
Hospital, Tokyo; M5, Tokyo Medical Center, Tokyo; M6, National Center
for Global Health and Medicine, Tokyo; M7, Sagamihara Hospital,
Kanagawa; M8, Yokohama Medical Center, Kanagawa; O9, Asahikawa
Medical Center, Hokkaido; O10, Hokkaido Medical Center, Hokkaido;
O11, Sendai Medical Center, Miyagi; O12, Matsumoto Medical Center,
Nagano; O13, Kanazawa Medical Center, Ishikawa; O14, Nagoya
Medical Center, Aichi; O15, Kyoto Medical Center, Kyoto; O16, Osaka
National Hospital, Osaka; O17, Osaka-Minami Medical Center, Osaka;
O18, Zentsuji Hospital, Kagawa; O19, Yonago Medical Center, Tottori;
O20, Okayama Medical Center, Okayama; O21, Kure Medical Center and
Chugoku Cancer Center, Hiroshima; O22, Kokura Medical Center,
Fukuoka; O23, Kyushu Medical Center, Fukuoka; O24, Beppu Medical
Center, Oita; O25, Oita Medical Center, Oita; O26, Kumamoto Medical
Center, Kumamoto; O27, Ureshino Medical Center, Saga; and O28,
Nagasaki Medical Center, Nagasaki.
Significance of this study
How might it impact on clinical practice in the foreseeable
future?
< It needs to be noted that subgenotype A2 infections are
spreading among sexually active generations in Japan.
< Although selective vaccination has prevented mother-to-baby
transmission of HBV since 1986, it does not contain sporadic
infections in Japan.
< Herd vaccination of younger generations needs to be
considered in Japan.
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determined in patients who were at high risk and gave consent
to testing.
Informed consent was obtained from each patient. The study
protocol conforms to the ethical guidelines of the 1975 Decla-
ration of Helsinki and the Ministry of Education, Culture,
Sports Science and Technology of Japan, and was approved by
the ethics committee of each institution.
Extraction of HBV DNA
HBV DNA was extracted from serum (100 ml) by the SMITEST
EX-R&D Nucleic Acid Extraction Kit (MBL Co, Nagoya, Japan)
and used for genotyping/subgenotyping and detecting muta-
tions in PreC and CP regions.
HBV genotypes
Genotypes were determined in Nagasaki Medical Center with
the SMITEST HBV Genotyping Kit (MBL) by hybridisation
with type-specific probes immobilised on a solid-phase
support.24
Determination of HBV subgenotypes
For subgenotyping, HBV DNA was amplified by PCR with
TaKaRa Ex Taq (Takara Bio, Shiga, Japan). PCR was performed
with appropriate nested primers to amplify a w1.2 kb sequence
in the preS1/S2/S gene (nucleotides 2854e835 in the reference
isolate (AB116077)). PCR products were purified, subjected to
cycle sequencing reaction with the BigDye Terminator v1.1
(Applied Biosystems, Tokyo, Japan), and applied to the DNA
sequencer (3100-Avant; Applied Biosystems).
Mutations in the PreC and CP regions
The A1896 mutation in the PreC region was detected by the
enzyme-linked minisequence assay (SMITEST HBV PreC ELMA;
Roche Diagnostics, Tokyo, Japan), and mutations in the CP
region for T1762/A1764 by the enzyme-linked specific probe
assay (SMITEST HBV Core Promoter Mutation Detection Kit;
Roche Diagnostics). The results were recorded as ‘wild-type’ and
‘mutant types’ dominantly expressed by HBV isolates.25
Phylogenetic analyses
Nucleotide sequences were aligned, and phylogenetic trees were
constructed by the CLUSTAL W program v1.83 (DDBJ home-
page: http://clustalw.ddbj.nig.ac.jp/top-j.html). The statistical
validity was assessed by bootstrap resampling with 1000 repli-
cates. Reference HBV strains were retrieved from the GenBank
database.
Statistical analysis
Results were expressed as percentage or mean6SD. Statistical
differences were evaluated by c2 and Fisher exact tests for
categorical variables, and analysis of variance and Scheffe’s test
for quantitative variables, using the SPSS software. The 95% CI,
for the difference in means, was calculated in analyses for
quantitative variables. p<0.05 was considered significant.
RESULTS
Distribution of HV genotypes
HBV genotypes were determined in the 547 patients with AHB.
The genotype was A in 137 (25.0%) patients (accompanied by G
in one (0.2%)), B in 48 (8.8%), C in 359 (65.6%), D in one (0.2%),
E in one (0.2%), and H in one (0.2%). Because HBV genotype G
is a defective virus and cannot replicate by itself,26 27 the single
patient with mixed genotypes A and G was included in the 137
patients with genotype A in further analyses. RNA of hepatitis
D virus was detected in three of the 453 (0.7%) patients. Anti-
HIV was examined in patients at high risk of infection and
detected in 14 of the 53 (26.4%) who gave consent to testing.
Demographic and clinical differences among patients infected
with HBV of distinct genotypes
Demographic and clinical characteristics of patients with
different genotypes are compared in table 1. There was no
difference in mean age among patients with genotypes A, B and
C. The proportion of men was higher in patients with genotype
A than B or C (94.2% vs 79.2%, p<0.05; or 56.0%, p<0.0001),
and in those with genotype B than C (79.2% vs 56.0%, p<0.05).
Maximum levels of total bilirubin were higher in patients
with genotype A than C (9.667.6 vs 7.166.2 mg/dl, p<0.05),
with a difference of 2.5 mg/dl (95% CI 0.93 to 4.08), whereas the
highest alanine aminotransferase activity and lowest PT values
did not differ among patients with distinct genotypes.
SAH developed in four (2.9%) patients with genotype A, four
(8.3%) with genotype B, and 26 (7.2%) with genotype C. FH
developed in one (2.1%) patient with genotype B and eight
(2.2%) with genotype C; no patients with genotype A developed
FH. Eight (1.5%) patients died, including one with genotype B
and seven with genotype C. There were no significant differ-
ences among patients with different genotypes in the frequency
of SAH or FH or mortality.
The outcome of AHB was traceable in 514 of the 547 (94.0%)
patients. Chronic infection with persistence of HBsAg for >6
months developed in five of the 123 (4.1%) patients with
genotype A (including the one accompanied by genotype G),
none of the 46 (0%) with genotype B, and none of the 342 (0%)
with genotype C; it was more common in patients with geno-
type A than C (p<0.05). HBV infection persisted exclusively in
the patients with genotype A, either alone (four patients) or
together with genotype G (one).
Among the five patients who acquired chronic HBV infection,
four (three with genotype A and one with mixed genotypes A
and G) were examined for anti-HIV, and one with genotype A
was found to be positive. HBV infection persisted in three
(including the one with anti-HIV) of the five patients for
>1 year after the onset, and the remaining two (both without
anti-HIV) cleared HBsAg from the serum after retaining it for
>6 months.
Mutations in the PreC and/or CP region were detected in 3.7%
(4/109) of patients with genotype A, 15.4% (6/39) of those with
genotype B, and 25.5% (79/310) of those with genotype C. They
were significantly less common in patients with genotype A
than B or C (A vs B, p<0.05; A vs C, p<0.0001). The only patient
with genotype A who had the PreC mutation was simulta-
neously infected with genotype G.
Routes of transmission were identifiable in 275 of the 547
(50%) patients, and the main route was heterosexual contacts;
those in the remaining patients could not be disclosed. The
frequency of heterosexual activity did not differ among patients
with distinct genotypes. However, homosexual activity was
more common in patients with genotype A than B or C (21.2%,
0% and 0.8%, respectively (A vs B, p<0.001; A vs C, p<0.0001)).
Among the 32 homosexual men, HBV genotype A was detected
in 29 (91%). Consent to anti-HIV testing was given by 10 of the
29 patients, and four of these (40%) were positive.
Longitudinal changes in the distribution of genotypes
Figure 2 illustrates changes in the distribution of HBV genotypes
through three 6-year periods over 18 years (1991e2008). In
addition, data from 2009 are shown. HBV genotype A accounted
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for 6% (9/150) in the 1st period, 15.4% (19/123) in the 2nd, and
39.4% (89/226) in the 3rd, with significant differences between
1st and 2nd (p<0.05), 2nd and 3rd (p<0.0001), and 1st and 3rd
(p<0.0001). Conversely, AHB associated with genotype C
decreased through three periods with significant differences,
while AHB associated with genotype B did not change
appreciably.
On the basis of these results, the yearly incidence in each of
the three 6-year periods is calculated to be: 25.0 cases including
1.5 with genotype A in the 1st period; 20.5 cases including 3.2
with genotype A in the 2nd; and 37.7 cases including 14.8 with
genotype A in the 3rd. Hence, the incidence of AHB had not
changed markedly over the 12 years from 1991 to 2002, but
increased thereafter until 2008. Of the increment in the 3rd
period of 17.2 (37.7 minus 20.5) cases, there were 11.6 (14.8
minus 3.2) with genotype A; they accounted for 67% (11.6/17.2)
of the recent increase in AHB.
Regional distributions and longitudinal changes in genotype A
Among the 183 patients from the capital region, the genotype
was A in 65 (35.5%), B in 22 (12.0%), C in 94 (51.4%), E in one
(0.5%), and H in one (0.5%) (table 2). Of the remaining 364
(66.5%) patients from other regions, by contrast, the genotype
was A in 72 (19.8%), B in 26 (7.1%), C in 265 (72.8%), and D in
one (0.3%). Genotype A was significantly more common in the
capital than in other regions (35.5% vs 19.8%, p<0.0001). In the
capital region, genotype A accounted for 4.8% (2/42) in the 1st
period, 29.3% (12/41) in the 2nd, and 50.0% (42/84) in the 3rd.
There were significant differences between the 1st and 2nd
periods (p<0.05), 2nd and 3rd (p<0.05), and 1st and 3rd
(p<0.0001). In other regions, by contrast, genotype A accounted
for 6.5% (7/108) in the 1st period, 8.5% (7/182) in the 2nd, and
33.1% (47/142) in the 3rd. For the first time in other regions,
genotype A increased in the 3rd period, in comparison with the
1st and 2nd (1st vs 3rd, p<0.0001; 2nd vs 3rd, p<0.0001).
Subgenotypes of genotype A
Of the 137 genotype A isolates, amplification and sequencing of
HBV DNA were feasible in 114 (83.2%); the isolate from the
single patient with genotypes A and G was excluded. A phylo-
genetic tree was constructed, on the entire preS1/S2/S genes of
w1.2 kb, for these 114 isolates along with 34 genotype A isolates
retrieved from the database (figure 3).
Of the 114 isolates in this study, 101 (88.6%) were subgeno-
type A2, and the remaining 13 (11.4%) were subgenotype A1. In
a pair-wise comparison, the sequence divergence among the 101
subgenotype A2 isolates was 0e1.3%, and that among the 13
subgenotype A1 isolates spanned 0% to 2.3%. The sequence
divergence between subgenotype A2 and A1 isolates ranged from
2.6% to 4.7%.
A sequence of 1203 nucleotides was possessed in common by
three of the 101 (3%) isolates of subgenotype A2. For conve-
nience, the group comprising these three isolates was labelled
‘identical group I’. Likewise, an additional six ‘identical groups’
were found, and numbered from ‘II’ to ‘VII’. They comprised 35
(35%), seven (7%), two (2%), three (3%), 12 (12%) and three
(3%) of the 101 isolates of subgenotype A2. In contrast, only one
identical group, designated ‘VIII’, was constructed by three of
the 13 (23%) isolates of subgenotype A1.
Some isolates of subgenotype A1 and A2 were obtained from
patients who had travelled to foreign countries in the recent past
(5/13 (38.5%) patients with A1 to Africa, Philippines, Myanmar
and China; and 5/101 (5.0%) patients with A2 to Europe,
Thailand, Brazil and the USA).
Table 1 Demographic and clinical characteristics of patients with acute hepatitis who were infected with HBV of different genotypes (1991e2009)
Feature Total (n[547)
HBV genotypes
A (n[137)y (25.0%) B (n[48) (8.8%) C (n[359) (65.6%) Others (n[3)z (0.5%)
Age (years) 35.6614.8 35.2612.2 39.6615.6 35.1615.5 49.7613.6
Male 367 (67.1%) 129 (94.2%){ * yy *** 38 (79.2%)yy * 201 (56.0%) 3 (100%)
ALT (IU/l)x 255361563 228961069 255761412 234261728 333362406
T-Bil (mg/dl)x 7.866.7 9.667.6yy* 7.767.4 7.166.2 9.062.5
PT (%)x 74.6622.6 75.2615.9 73.8624.5 74.7624.5 15.8zz
Severe hepatitis 34 (6.2%) 4 (2.9%) 4 (8.3%) 26 (7.2%) 0 (0.0%)
Fulminant hepatitis 10 (1.8%) 0 (0.0%) 1 (2.1%) 8 (2.2%) 1 (33.3%)
Mortality 8 (1.5%) 0 (0.0%) 1 (2.1%) 7 (1.9%) 0 (0.0%)
HBsAg persisting >6 months 5/514 (1.0%) 5/123 (4.1%)yy * 0/46 (0.0%) 0/342 (0%) 0/3 (0.0%)
PreC/CP mutations
PreC 43/461 (9.3%) 1/109 (0.9%){ * yy * 6/39 (15.4%) 34/310 (11.0%) 2/3 (66.7%)
CP 69/461 (15.0%) 3/109 (2.8%)yy *** 0/39 (0.0%)yy * 63/310 (20.3%) 3/3 (100%)
PreC and/or CP 92/461 (20.0%) 4/109 (3.7%){ * yy *** 6/39 (15.4%) 79/310 (25.5%) 3/3 (100%)
Transmission route
Homosexual 32 (5.9%) 29 (21.2%){ ** yy *** 0 (0.0%) 3 (0.8%) 0 (0.0%)
Heterosexual 217 (39.5%) 52 (38.0%) 25 (52.1%) 139 (39.6%) 1 (33.3%)
Medical procedure 16 (2.9%) 2 (1.5%) 2 (4.2%) 12 (3.3%) 0 (0.0%)
Other 10 (1.8%) 1 (0.7%) 1 (2.1%) 7 (1.9%) 1 (33.3%)
Undetermined 272 (49.7%) 53 (38.7%)yy * 20 (41.7%) 198 (55.2%) 1 (33.3%)
Anti-HIV 14/53 (26.4%) 11/35 (31.4%) 0/3 (0.0%) 3/15 (20.0%) 0/0
Values are mean6SD or number (%).
yOne patient with genotype A was simultaneously infected with genotype G.
zEach patient was infected with genotype D, E or H.
xHighest values during the clinical course are shown for ALT and T-Bil, and lowest values for PT.
Statistical analysis was performed to compare genotypes A, B and C.
{Significantly different compared with genotype B.
yySignificantly different compared with genotype C.
*p<0.05, **p<0.001, ***p<0.0001.
zzData from the patient with genotype E only.
ALT, alanine aminotransferase; CP, core promoter; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; PreC, precore; PT, prothrombin time; T-Bil, total bilirubin.
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Subgenotypes of genotype B
Of the 48 isolates of genotype B, subgenotyping was feasible in
43 (90.0%). A phylogenetic tree was constructed on preS1/S2/S-
gene sequences from these 43 isolates, along with those from 25
isolates of genotype B retrieved from the database (figure 4). Of
the 43 isolates in this study, 10 (23.3%) were subgenotype B1, 28
(65.1%) were B2, two (4.7%) were B3, and three (7.0%) were B4.
In a pair-wise comparison, the sequence divergence among 10
subgenotype B1 isolates ranged from 0.4% to 1.4%, and that
among 28, two and three isolates of subgenotypes B2, B3 and
B4 spanned 0e1.7%, 0.5% and 0.6e0.8%, respectively. The
inter-subgenotype divergence among B1eB4 ranged from 0.6%
to 4.4%.
One ‘identical group’ made up of five isolates was detected
among the 28 of subgenotype B2; it was named ‘IX’. In contrast,
no ‘identical group’ was found in 10, two or three isolates of
subgenotype B1, B3 or B4.
Some isolates of subgenotypes B2, B3 and B4 were obtained
from patients who had travelled to foreign countries in the
recent past (7/28 (25.0%) patients with B2 to China and other
countries; 1/2 (50.0%) patients with B3 to a country unknown;
and 1/3 (33.3%) patients with B4 to Vietnam). However, none of
the 10 subgenotype B1 isolates was associated with travel to
foreign countries.
Identical groups
The proportion of isolates that shared a sequence in identical
groups was higher for subgenotype A2 (64.4%) than for A1, B1,
B2, B3 or B4 (23.1%, 0%, 17.9%, 0% or 0%, respectively (A2 vs
A1, p<0.001; A2 vs B1, p<0.0001; A2 vs B2, p<0.0001)).
Homosexual activity was more common in patients belonging
to the seven identical groups than the non-identical group of
subgenotype A2 (17/65 (26.2%) vs 3/36 (8.3%), p<0.05). Among
the isolates in the seven identical groups of subgenotype A2,
those in groups I, III and VII clustered locally during short
periods of 2e7 years. In contrast, subgenotype A2 isolates in
groups II and VI were scattered widely over longer periods of
11e16 years.
DISCUSSION
In Japan, as in most Asian countries, the persistent HBV carrier
state had been established mainly through perinatal trans-
mission from mother to baby and horizontal infection during
infancy. In 1986, a national prevention programme was
launched in Japan with selective vaccination of babies born to
carrier mothers with hepatitis B e antigen (HBeAg). In 1995, this
was extended to babies born to HBeAg-negative carrier mothers.
As a result, the prevalence of HBsAg among younger people born
since 1986 has decreased dramatically.28 29 However, there are an
Figure 2 Distribution of hepatitis B
virus (HBV) genotypes in three periods.
Table 2 Changes in the distribution of genotype A compared between the capital region and other regions over three periods
Area n
1st Period 2nd Period 3rd Period
2009(1991e1996) (1997e2002) (2003e2008)
Capital region 65/183 (35.5%)y*** 2/42 (4.8%)z* x*** 12/41 (29.3%)y* x* 42/84 (50.0%)y* 9/16 (56.3%)
Other regions 72/364 (19.8%) 7/108 (6.5%)x*** 7/82 (8.5%)x*** 47/142 (33.1%) 11/32 (34.4%)
Total 137/547 (25.0%) 9/150 (6.0%)z* x*** 19/123 (15.4%)x*** 89/226 (39.4%) 20/48 (41.7%)
Statistical analysis of the differences between the capital and other regions was performed, as well as through the 1st, 2nd and 3rd periods.
ySignificantly different compared with other regions.
zSignificantly different compared with the 2nd period.
xSignificantly different compared with the 3rd period.
*p<0.05, ***p<0.0001.
Tamada Y, Yatsuhashi H, Masaki N, et al. Gut (2011). doi:10.1136/gutjnl-2011-300832 5 of 9
Viral hepatitis
estimated one million HBV carriers in Japan at present.30
Furthermore, many Japanese remain at increased risk of hori-
zontal infection with HBV, because they have not received
selective vaccination and therefore do not have the antibody to
HBsAg. Because AHB is extremely under-reported and no
national surveillance data are available in Japan, the incidence
has not been determined accurately. In the USA, the incidence of
AHB has decreased markedly since the adoption of a compre-
hensive immunisation strategy in 1991.31 32
In the present study over 1991e2009, we conducted
a nationwide, sentinel surveillance on AHB in Japan. In the 547
patients recruited over 19 years, genotype C was the most
prevalent (65.6%), followed by genotype A (25.0%) and geno-
type B (8.8%). Demographic and clinical differences were
observed among patients with genotypes A, B and C (table 1).
The proportion of men reached 94.2% for genotype A infection,
higher than that for genotype B (79.2%) or C (56.0%) infection.
In the analysis of the route of transmission, homosexual activity
was reported by 21.2% of patients with genotype A; all were
male. In general, sexual activity tends to be higher in men than
women. The predominance of genotype A in men may be
attributable to a high frequency of homosexual activity among
men.
Although adult-acquired HBV infection persists at a high
frequency of w10% in European countries and the USA,33 it
rarely, if ever, becomes chronic in Japan. Recent studies suggest
that the chance of a chronic outcome of AHB may differ by HBV
genotype21 34; it is more common for genotype A than other
genotypes.22 35 36 In the present study, HBV infection persisted
in 4.1% of patients with genotype A, in comparison with 0% of
Figure 3 Phylogenetic analysis of
genotype A strains by the neighbour-
joining method. Isolates obtained in this
study are shown in bold with asterisks.
Hospitals in the capital region are
labelled M1eM8 and those in other
regions O9eO28 (corresponding to
those in figure 1). Year of onset is
indicated by the last two digits after the
first hyphen. Numbers after the second
hyphen represent the identification
numbers of patients in each year (not
always consecutive). Transmission
routes are shown in lower-case letters
in parentheses: h, homosexual; s,
heterosexual; m, medical procedure; o,
others; and u, undetermined. Isolates
with identical sequences are bracketed
in ‘Identical groups I through VIII’ on the
tree. Each bracket is divided by areas
and periods. Reference hepatitis B virus
(HBV) isolates, including 12 of
subgenotype A1 and 22 of subgenotype
A2, were obtained from the database
and specified by their accession
numbers, isolate names and countries
of origin. Bootstrap values are indicated
on major phylogenetic branches.
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those with genotype C. Remarkably, all five patients with AHB
who acquired chronic infection possessed HBV genotype A,
either alone (four patients) or together with HBV genotype G
(one). Increasing genotype A infections may have changed the
genotype distribution in patients with AHB and those with
chronic HBV infection. In Japanese patients with chronic
hepatitis B, the proportion of genotype A has doubled, from
1.7% in 1999e2000 to 3.5% in 2005e2006.37
The genotype was A in 29 of the 32 (91%) homosexual men.
Of the 29 homosexuals with genotype A, 10 gave consent to
anti-HIV testing, and four of these (40%) were found to be
positive. Of the five patients who acquired chronic HBV infec-
tion, anti-HIV was tested in four (three with genotype A and
one with genotypes A and G), and one with genotype A was
found to be positive. There is a possibility that co-infecting HIV
in this patient with genotype A may have promoted chronic
HBV infection; HIV is known to prolong and aggravate HBV
infection by compromising immune responses.38
Patients with FH in this study were infected with either HBV
genotype B (1/48 (2.1%)) or C (8/359 (2.2%)); no patients with
genotype A developed FH. PreC and/or CP mutations were
significantly less common in genotype A (1/109 (3.7%)) than B
(6/39 (15.4%)) or C (279/310 (5.5%)) infection. The single
patient with genotype A who had PreC mutation was simul-
taneously infected with HBV genotype G. There is a possibility
that the PreC mutation in this patient was from HBV genotype
G.26 FH did not develop in any patients with genotype A,
which may be attributable, at least in part, to the lack of PreC
mutation in genotype A infections.39
Previous reports have shown that genotype A is common in
patients with AHB in Metropolitan Tokyo,20 21 40 as well as
around Aichi located in the middle of Mainland Japan.22
Figure 4 Phylogenetic analysis of
genotype B strains by the neighbour-
joining method. Hepatitis B virus (HBV)
isolates obtained in the present study
are specified in the same manner as in
figure 3, and isolates with an identical
sequence are bracketed in ‘Identical
group IX’ on the tree. Of them, 10
reference isolates of subgenotype B1
and 13, two and two of those of B2, B3
and B4, respectively, were retrieved
from the database; they are specified as
in figure 3.
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Yotsuyanagi et al23 reported that genotype A is more common in
patients with AHB in the metropolitan region than in other
regions. Sugauchi et al41 found that, in patients with AHB, the
proportion with genotype A has increased over time. The
present study indicates that the number of patients with AHB
in Japan would not have decreased. We found that the propor-
tion of patients with genotype A infection is increasing in the 28
national hospitals in Japan (6.0% in the 1st period, 15.4% in the
2nd, and 39.4% in the 3rd (figure 2)), with the prevalence
much higher in the capital than other regions (35.5% vs 19.8%
(table 2)).
In this study, there was a time lag in the increase in genotype
A infection between the capital region and other regions of
Japan (table 2). In the capital region, the prevalence of genotype
A started to increase in the late 1990s, and kept increasing
through the early 2000s (4.8% in the 1st period, 29.3% in the
2nd, 50.0% in the 3rd, and 56.3% in 2009). In other regions, by
contrast, the frequency of genotype A did not change during the
late 1990s, and increased significantly in the 2000s (6.5% in the
1st period, 8.5% in the 2nd, 33.1% in the 3rd, and 34.4% in
2009). Thus infiltration of genotype A infection into other
regions occurred 5e6 years behind the epidemic in the capital
region. This indicates that genotype A infection originated in the
capital region and then spread to other areas of Japan.
Some genotypes are classified into several subgenotypes, and
they have distinct geographical distributions.42 Hence, subge-
notypes are useful in tracing the route of HBV infection. By
phylogenetic analysis (figures 3 and 4), 88.6% of genotype A
isolates had the EuropeaneAmerican type (A2), and the
remaining 11.4% possessed the AsianeAfrican type (A1). Like-
wise, 76.7% of genotype B isolates had Asian types (B2eB4), and
the remaining 23.3% possessed the type endemic to Japan (B1).
Of the 157 HBV isolates of genotype A or B, 147 (93.6%) had
subgenotypes foreign to Japan. They are thought to have been
transmitted from foreign sex workers, and spread among certain
populations who share particular sexual behaviours in Japan.41
Of note, some HBV isolates of distinct subgenotypes
possessed an identical sequence in the preS1/S2/S gene. The
isolates of subgenotype A2 were prominent in this regard, and
more often had the same sequence than those of other subge-
notypes, such as A1, B1 and B2. The high prevalence of subge-
notype A2 isolates with an identical sequence would not have
been caused by cross-contamination. If cross-contamination had
occurred, it would have affected isolates of all subgenotypes, and
not influenced subgenotype A2 isolates preferentially. As many
as 35% of subgenotype A2 isolates had an identical sequence,
and those with the same sequence increased to 56.3% in the
recent 2009 survey in Metropolitan Tokyo. Furthermore, some
subgenotype A2 isolates in groups I, III and VII clustered locally
within short periods, whereas others in groups II and VI were
scattered widely over a long period of time. On the basis of these
results, it is tempting to speculate that some subgenotype A2
strains would have been transmitted from person to person
without undergoing mutations for many years.
In summary, the present study indicates the following. (1)
AHB in the 28 national hospitals in Japan has not decreased,
because genotype A infections are increasing. (2) Genotype A
infections started to increase in the capital region, and then
spread to local areas 5e6 years later. (3) Approximately 90% of
genotype A in patients with AHB is subgenotype A2. (4)
Subgenotype A2 strains with an identical sequence are spreading
among younger generations with high sexual activity. (5) On the
basis of the results obtained, AHB in Japan is not decreasing,
because HBV of subgenotype A2 is prevailing in particular
subpopulations at high risk. Finally, in order to prevent further
increases in AHB in Japan, universal vaccination of young people
deserves consideration.
Author affiliations
1Clinical Research Center, NHO Nagasaki Medical Center, Nagasaki, Japan
2Department of Hepatology, Nagasaki University Graduate School of Biomedical
Sciences, Nagasaki, Japan
3National Center for Global Health and Medicine, Tokyo, Japan
4NHO Kyushu Medical Center, Fukuoka, Japan
5NHO Osaka National Hospital, Osaka, Japan
6NHO Yokohama Medical Center, Kanagawa, Japan
7NHO Sagamihara Hospital, Kanagawa, Japan
8NHO Oita Medical Center, Oita, Japan
9NHO Nagoya Medical Center, Aichi, Japan
10NHO Osaka-Minami Medical Center, Osaka, Japan
11NHO Kokura Medical Center, Fukuoka, Japan
12NHO Sendai Medical Center, Miyagi, Japan
13NHO Kyoto Medical Center, Kyoto, Japan
14NHO Tokyo Medical Center, Tokyo, Japan
15NHO Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan
16NHO Kanazawa Medical Center, Ishikawa, Japan
17NHO National Disaster Medical Center, Tokyo, Japan
18Miyakawa Memorial Research Foundation, Tokyo, Japan
Acknowledgements We thank participating physicians (MD) in the JNHAHSG for
collaborating, with data and sample collection: Hideo Nishimura, Asahikawa Medical
Center; Yukio Ohhara, Hokkaido Medical Center; Masakazu Kobayashi, and the late
Takeshi Sodeyama, Matsumoto Medical Center; Fujio Makita, Nishigunma Hospital;
Takeo Saoshiro, and Akira Saito, Nishisaitama-Chuo Hospital; Michiyasu Yagura, and
the late Hideharu Harada, Tokyo Hospital; Keiichi Hirata, National Disaster Medical
Center; Yoko Nakamura, Sagamihara Hospital; the late Hideo Morimoto, Kanazawa
Medical Center; Noboru Hirashima, Higashi Nagoya National Hospital; Michio Kato,
Osaka National Hospital; Tetsuo Yamamoto, Yonago Medical Center; Haruhiro
Yamashita, Okayama Medical Center; Hirotaka Kouno and Eiichi Takezaki, Kure
Medical Center and Chugoku Cancer Center; Toru Hayashi, and Shuji Oda, Zentsuji
Hospital; Akihide Masumoto, Kokura Medical Center; Hironori Sakai, Beppu Medical
Center; Koichi Honda, Oita Medical Center; Kazuhiro Sugi, Kumamoto Medical
Center; Michiaki Koga, and Hiroaki Kawasoe, Ureshino Medical Center; Michitami
Yano, and Manabu Daikoku, Nagasaki Medical Center. All the hospitals belong to
National Hospital Organization (NHO). We appreciate the excellent technical
assistance of Ms Rumiko Hamada, Ms Yuka Jiuchi, Ms Mika Fukuda and Ms Rumiko
Nakao. Finally, we express our deep gratitude to the late Dr Koji Yano (Nagasaki
Medical Center) for his contribution to the design and coordination of this study, and
we dedicate this article to him.
Funding This study was supported by a grant-in-aid from the National Hospital
Organization (grant number H21-NHO(Kan)-03).
Competing interests None.
Ethics approval Approved by the ethics committee of each institution.
Contributors YT, HY and HI designed data collection tools, monitored data collection
for the whole study, wrote the statistical analysis plan, cleaned and analysed the data.
YT, HY and YM drafted and revised the paper. HY, NM, MN, EM, TK, YW, TM, MS,
TH, TS, YM, TK, MT, HK, HO, SH and SA collaborated in data and sample collection.
Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES
1. Arauz-Ruiz P, Norder H, Robertson BH, et al. Genotype H: a new Amerindian
genotype of hepatitis B virus revealed in Central America. J Gen Virol
2002;83:2059e73.
2. Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic
relatedness, and structural proteins of six strains of the hepatitis B virus, four of
which represent two new genotypes. Virology 1994;198:489e503.
3. Okamoto H, Tsuda F, Sakugawa H, et al. Typing hepatitis B virus by homology in
nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol
1988;69:2575e83.
4. Olinger CM, Jutavijittum P, Hubschen JM, et al. Possible new hepatitis B virus
genotype, southeast Asia. Emerg Infect Dis 2008;14:1777e80.
5. Stuyver L, De Gendt S, Van Geyt C, et al. A new genotype of hepatitis B virus:
complete genome and phylogenetic relatedness. J Gen Virol 2000;81:67e74.
6. Tran TT, Trinh TN, Abe K. New complex recombinant genotype of hepatitis B virus
identified in Vietnam. J Virol 2008;82:5657e63.
7. Tatematsu K, Tanaka Y, Kurbanov F, et al. A genetic variant of hepatitis B virus
divergent from known human and ape genotypes isolated from a Japanese patient
and provisionally assigned to new genotype J. J Virol 2009;83:10538e47.
8 of 9 Tamada Y, Yatsuhashi H, Masaki N, et al. Gut (2011). doi:10.1136/gutjnl-2011-300832
Viral hepatitis
8. Chu CJ, Lok AS. Clinical significance of hepatitis B virus genotypes. Hepatology
2002;35:1274e6.
9. Kao JH. Hepatitis B viral genotypes: clinical relevance and molecular characteristics.
J Gastroenterol Hepatol 2002;17:643e50.
10. Miyakawa Y, Mizokami M. Classifying hepatitis B virus genotypes. Intervirology
2003;46:329e38.
11. Kimbi GC, Kramvis A, Kew MC. Distinctive sequence characteristics of subgenotype
A1 isolates of hepatitis B virus from South Africa. J Gen Virol 2004;85:1211e20.
12. Kramvis A, Weitzmann L, Owiredu WK, et al. Analysis of the complete genome of
subgroup A’ hepatitis B virus isolates from South Africa. J Gen Virol 2002;83:835e9.
13. Sugauchi F, Kumada H, Acharya SA, et al. Epidemiological and sequence
differences between two subtypes (Ae and Aa) of hepatitis B virus genotype A. J
Gen Virol 2004;85:811e20.
14. Sugauchi F, Kumada H, Sakugawa H, et al. Two subtypes of genotype B (Ba and Bj)
of hepatitis B virus in Japan. Clin Infect Dis 2004;38:1222e8.
15. Sugauchi F, Orito E, Ichida T, et al. Epidemiologic and virologic characteristics of
hepatitis B virus genotype B having the recombination with genotype C.
Gastroenterology 2003;124:925e32.
16. Tanaka Y, Orito E, Yuen MF, et al. Two subtypes (subgenotypes) of hepatitis B virus
genotype C: a novel subtyping assay based on restriction fragment length
polymorphism. Hepatol Res 2005;33:216e24.
17. Akuta N, Suzuki F, Kobayashi M, et al. The influence of hepatitis B virus genotype on
the development of lamivudine resistance during long-term treatment. J Hepatol
2003;38:315e21.
18. Tanaka Y, Hasegawa I, Kato T, et al. A case-control study for differences among
hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D. Hepatology
2004;40:747e55.
19. Orito E, Ichida T, Sakugawa H, et al. Geographic distribution of hepatitis B virus
(HBV) genotype in patients with chronic HBV infection in Japan. Hepatology
2001;34:590e4.
20. Kobayashi M, Arase Y, Ikeda K, et al. Viral genotypes and response to interferon in
patients with acute prolonged hepatitis B virus infection of adulthood in Japan.
J Med Virol 2002;68:522e8.
21. Ogawa M, Hasegawa K, Naritomi T, et al. Clinical features and viral sequences of
various genotypes of hepatitis B virus compared among patients with acute hepatitis
B. Hepatol Res 2002;23:167e77.
22. Takeda Y, Katano Y, Hayashi K, et al. Difference of HBV genotype distribution
between acute hepatitis and chronic hepatitis in Japan. Infection 2006;34:201e7.
23. Yotsuyanagi H, Okuse C, Yasuda K, et al. Distinct geographic distributions of
hepatitis B virus genotypes in patients with acute infection in Japan. J Med Virol
2005;77:39e46.
24. Kato H, Orito E, Sugauchi F, et al. Frequent coinfection with hepatitis B virus strains
of distinct genotypes detected by hybridization with type-specific probes immobilized
on a solid-phase support. J Virol Methods 2003;110:29e35.
25. Orito E, Mizokami M, Sakugawa H, et al. A case-control study for clinical and
molecular biological differences between hepatitis B viruses of genotypes B and C.
Japan HBV Genotype Research Group. Hepatology 2001;33:218e23.
26. Kato H, Orito E, Gish RG, et al. Hepatitis B e antigen in sera from individuals infected
with hepatitis B virus of genotype G. Hepatology 2002;35:922e9.
27. Sugiyama M, Tanaka Y, Sakamoto T, et al. Early dynamics of hepatitis B virus in
chimeric mice carrying human hepatocytes monoinfected or coinfected with
genotype G. Hepatology 2007;45:929e37.
28. Koyama T, Matsuda I, Sato S, et al. Prevention of perinatal hepatitis B virus
transmission by combined passive-active immunoprophylaxis in Iwate, Japan
(1981e1992) and epidemiological evidence for its efficacy. Hepatol Res
2003;26:287e92.
29. Noto H, Terao T, Ryou S, et al. Combined passive and active immunoprophylaxis for
preventing perinatal transmission of the hepatitis B virus carrier state in Shizuoka,
Japan during 1980e1994. J Gastroenterol Hepatol 2003;18:943e9.
30. Tanaka J, Kumagai J, Katayama K, et al. Sex- and age-specific carriers of hepatitis
B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time
blood donors during 1995e2000. Intervirology 2004;47:32e40.
31. Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitisdUnited
States, 2007. MMWR Surveill Summ 2009;58:1e27.
32. Goldstein ST, Alter MJ, Williams IT, et al. Incidence and risk factors for acute
hepatitis B in the United States, 1982e1998: implications for vaccination programs.
J Infect Dis 2002;185:713e19.
33. Sherlock S. The natural history of hepatitis B. Postgrad Med J 1987;63 Suppl
2:7e11.
34. Mayerat C, Mantegani A, Frei PC. Does hepatitis B virus (HBV) genotype influence
the clinical outcome of HBV infection? J Viral Hepat 1999;6:299e304.
35. Hayashi K, Katano Y, Takeda Y, et al. Association of hepatitis B virus subgenotypes
and basal core promoter/precore region variants with the clinical features of patients
with acute hepatitis. J Gastroenterol 2008;43:558e64.
36. Ozasa A, Tanaka Y, Orito E, et al. Influence of genotypes and precore mutations on
fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology
2006;44:326e34.
37. Matsuura K, Tanaka Y, Hige S, et al. Distribution of hepatitis B virus genotypes
among patients with chronic infection in Japan shifting toward an increase of
genotype A. J Clin Microbiol 2009;47:1476e83.
38. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency
virus type 1 infection on the development of the hepatitis B virus carrier state.
J Infect Dis 1991;163:1138e40.
39. Li JS, Tong SP, Wen YM, et al. Hepatitis B virus genotype A rarely circulates as an
HBe-minus mutant: possible contribution of a single nucleotide in the precore region.
J Virol 1993;67:5402e10.
40. Suzuki Y, Kobayashi M, Ikeda K, et al. Persistence of acute infection with hepatitis B
virus genotype A and treatment in Japan. J Med Virol 2005;76:33e9.
41. Sugauchi F, Orito E, Ohno T, et al. Spatial and chronological differences in hepatitis
B virus genotypes from patients with acute hepatitis B in Japan. Hepatol Res
2006;36:107e14.
42. Norder H, Courouce AM, Coursaget P, et al. Genetic diversity of hepatitis B virus
strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes.
Intervirology 2004;47:289e309.
PAGE fraction trail=8.75
Tamada Y, Yatsuhashi H, Masaki N, et al. Gut (2011). doi:10.1136/gutjnl-2011-300832 9 of 9
Viral hepatitis
